Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Short-term Investments (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Short-term Investments for 9 consecutive years, with $67.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 113.86% year-over-year to $67.9 million, compared with a TTM value of $67.9 million through Dec 2025, up 113.86%, and an annual FY2025 reading of $67.9 million, up 113.86% over the prior year.
  • Short-term Investments was $67.9 million for Q4 2025 at Puma Biotechnology, up from $2.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $67.9 million in Q4 2025 and bottomed at $2.1 million in Q3 2025.
  • Average Short-term Investments over 5 years is $20.0 million, with a median of $12.9 million recorded in 2023.
  • The sharpest move saw Short-term Investments skyrocketed 812.42% in 2024, then crashed 92.9% in 2025.
  • Year by year, Short-term Investments stood at $19.0 million in 2021, then plummeted by 74.32% to $4.9 million in 2022, then soared by 133.0% to $11.4 million in 2023, then surged by 179.6% to $31.7 million in 2024, then soared by 113.86% to $67.9 million in 2025.
  • Business Quant data shows Short-term Investments for PBYI at $67.9 million in Q4 2025, $2.1 million in Q3 2025, and $41.4 million in Q2 2025.